Infectious pulmonary complications in HIV-infected patients in the high by active antiretroviral therapy era in Spain;Complicaciones infecciosas pulmonares en los pacientes con infección por el virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad en España

Medicina Clinica

Volumn 125, Issue 14, 2005, Pages 548-555

  Benito Hernández, Natividad ^a,b   Moreno Camacho, Asunción ^a   Gatell Artigas, José María ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b NONE   (Spain)

Author keywords

AIDS; HIV; Mycobacteriosis; Pneumocystis jiroveci pneumonia (Pneumocystis carinii); Pneumonia; Pulmonary complications; Pulmonary infiltrates; Tuberculosis

Indexed keywords

BACTERIAL PNEUMONIA; DIAGNOSTIC PROCEDURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION COMPLICATION; LOBAR PNEUMONIA; LUNG INFECTION; LUNG TUBERCULOSIS; OUTCOMES RESEARCH; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS JIROVECI; PROGNOSIS; PSEUDOMONAS AERUGINOSA; REVIEW; SPAIN; SUPERINFECTION;

EID: 28544450603     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13080461     Document Type: Review

References (136)

1. CDC. Pneumocystis carinii pneumonia -Los Angeles. MMWR. 1981; 30:250-2.
2. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for pneumocystis from humans. Emerg Infect Dis. 2002;8:891-6.
3. Centers for Disease Control and Prevention. HIV and AIDS -United States, 1981-2000. MMWR. 2001;50:430-4.
4. Centers for Disease Control and Prevention. The global HIV and AIDS epidemic, 2001. MMWR. 2001;50:434-9.
5. ONUSIDA/OMS, 2003. Programa Conjunto de las Naciones Unidas sobre el VIH/sida (ONUSIDA). Organización Mundial de la Salud (OMS). ONUSIDA/03.39S (versión española, diciembre de 2003). Versión original inglesa, UNAIDS/03.39E, diciembre de 2003: AIDS epidemic update: December 2003.
6. 2004 Report on the global AIDS epidemic. Geneva: Joint United Nations Program on HIV/AIDS, July 2004.
7. The world health report 2004. Changing history. Geneva: World Health Organization, May 2004. Disponible en: http://www.who.int/whr
8. Instituto de Salud Carlos III. Centro Nacional de Epidemiología. Ministerio de Sanidad y Consumo. Dirección General de Salud Pública. Secretaría del Plan Nacional sobre el sida. Vigilancia epidemiológica del sida en España. Registro nacional de casos del sida. Actualización a 21 de Diciembre de 2003. Informe semestral n.° 2, Año 2003. Disponible en: http://cne.isciii.es/sida/informe.pdf
9. Instituto de Salud Carlos III. Centro Nacional de Epidemiología. Ministerio de Sanidad y Consumo. Dirección General de Salud Pública. Secretaría del Plan Nacional sobre el sida. Resumen de la evolución de la epidemia de VIH y sida en España. Disponible en: http://cne.isciii.es/ sida/vih5.htm
10. Murray JF, Felton CP, Garay SM, Gottlieb MS, Hopewell PC, Stover DE, et al. Pulmonary complications of the acquired immunodeficiency syndrome: report of a National Heart, Lung, and Blood Institute workshop. N Engl J Med. 1984;310:1682-8.
11. Stover DE, White DA, Romano PA, Gellenee RA, Robeson WA. Spectrum of pulmonary diseases associated with the acquired immune deficiency syndrome. Am J Med. 1985;78:429-37.
12. Murray JF, Garay SM, Hopewell PC, Mills J, Snider GL, Stover DE. NHLBI workshop summary. Pulmonary complications of the acquired syndrome: an update. Am Rev Respir Dis. 1987;135:504-9.
13. Meduri GU, Stein DS. Pulmonary manifestations of acquired immunodeficiency syndrome. Clin Infect Dis. 1992;14:98-113.
14. Miller R. HIV-associated respiratory diseases. Lancet. 1996;348:307-12.
15. Afessa B, Greaves W, Gren W, Oloponeic L, Saxinger C, Frederick W. Autopsy findings in HIV-infected inner city patients. J Acquir Immune Defic Syndr. 1992;5:132-6.
16. Masliah E, DeTeresa RM, Mallory ME, Hansen LA. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 2000;14:69-74.
17. Feikin DR, Feldman C, Schuchat A, Janoff EN. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis. 2004;4:445-55.
18. Gold JA, Rom WN, Harkin TJ. Significance of abnormal chest radiograph findings in patients with HIV-1 infection without respiratory simptoms. Chest. 2002;121:1472-7.
19. Osmond DH, Chin DP, Glassroth J, Kvale PA, Wallace JM, Rosen MJ, et al. Impact of bacterial pneumonia and Pneumocystis carinii pneumonia on human immunodeficiency virus disease progression. Clin Infect Dis. 1999;29:536-43.
20. Kaplan JE, Janoff EN, Masur H. Do bacterial pneumonia and Pneumocystis carinii pneumonia accelerate progression of human immunodeficiency virus disease? Clin Infect Dis. 1999;29:544-6.
21. Shaunak S, Veryard C, Javan C. Severe Pneumocystis carinii pneumonia increases the infectious titre of HIV-1 in blood and can promote the expansion of viral chemokine co-receptor tropism. J Infect. 2001;43:3-6.
22. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Crit Care Med. 1995;151:129-35.
23. Del Amo J, Perez-Hoyos S, Hernández Aguado I, Díez M, Castilla J, Porter K, et al. Impact of tuberculosis on HIV disease progression in persons with well-documented time of HIV seroconversion. J Acquir Immune Defic Syndr. 2003;33:184-90.
24. Wallace JM, Rao AV, Glassroth J, Hausen NI, Rosen MJ, Arakaki C, et al, and the Pulmonary Complications of HIV Infections Study Group. Respiratory illness in persons with human immunodeficiency virus infection. Am Rev Respir Dis. 1993;148:1523-9.
25. Wallace JM, Hansen NI, Lavange L, Glassroth J, Browdy BL, Rosen MJ, et al. Respiratory disease trends in the pulmonary complications of HIV infection study cohort. Am J Respir Crit Care Med. 1997;155:72-80.
26. Daley CL, Mugusi F, Chen LL, Schmidt DM, Small PM, Bearer E, et al. Pulmonary complications of HIV infection in Dar es Salaam, Tanzania. Role of bronchoscopy and bronchoalveolar lavage. Am J Respir Crit Care Med. 1996;154:105-10.
27. Salzman SH. Bronchoscopic and other invasive sampling techniques in the diagnosis of pulmonary complications of HIV infection. En: Rosen MJ, Beck JM, editors. Human immunodeficiency virus and the lung. New York: Marcel Dekker; 1998. p. 195-227.
28. Serraino D, Puro V, Boumis E, Angeletti C, Girardi E, Petrosillo N, et al. Epidemiological aspects of major opportunistic infections of the respiratory tract in persons with AIDS: Europe, 1993-2000. AIDS. 2003; 17:2109-16.
29. Kamanfu G, Mlika-Cabanne N, Girard PM, Nimubona S, Mpfizi B, Cishako A, et al. Pulmonary complications of human immunodeficiency virus infection in Bujumbura, Burundi. Am Rev Respir Dis. 1993;147: 658-63.
30. Lucas S, Goodgame R, Kocjan G, Serwadda D. Absence of pneumocystosis in Ugandan AIDS patients. AIDS. 1989;3:47-8.
31. Batungwanayo J, Taelman H, Lucas S, Bogaerts J, Alard D, Kagame A, et al. Pulmonary disease associated with the human immunodeficiency virus in Kigali, Rwanda. Am J Respir Crit Care Med. 1994;149:1591-6.
32. Mcleod DT, Neill P, Robertson VJ, Latif AS, Emmanuel JC, Els JE, et al. Pulmonary diseases in patients in patients infected with the human immunodeficiency virus in Zimbabwe, Central Africa. Trans Roy Soc Trop Hyg. 1989;83:694-7.
33. Carme B, Mboussa J, Andzin M, Mbouni E, Mpele P, Datry A. Pneumocystis carinii is rare in AIDS in Central Africa. Trans Roy Soc Trop Med Hyg. 1991;85:80.
34. Centers for Diseases Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR. 1989;38 (Suppl 5):1-9.
35. Muñoz A, Schrager LK, Bacellar H, Speizer I, Vermund SH, Detels R, et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. Am J Epidemiol. 1993;137:1985-91.
36. Stein M, O'Sullivan P, Wachtel T, Fisher A, Mikolich D, Sepe S, et al. Causes of death in persons with human immunodeficiency virus infection. Am J Med. 1992;93:387-90.
37. Chien SM, Rawji M, Mintz S, Rachils A, Chan CK. Changes in hospital admissions pattern in patients with human immunodeficiency virus infection in the era of Pneumocystis carinii prophilaxis. Chest. 1992; 102:1035-9.
38. Cohn DL. Bacterial pneumonia in the HIV-infected patient. Infect Dis Clin North Am. 1991 5:485-507.
39. Hardy WD, Feinberg J, Finkelstein DM, Power ME, He W, Kaczka C, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med. 1992;327:1842-8.
40. Tabet SR, Krone MR, Hooton TM, Koutsky LA, Holmes KK. Bacterial infections in adult patients hospitalized with AIDS: case-control study of prophylactic efficacy of trimethoprim-sulfamethoxazole versus aerosolized pentamidine. Int J STD AIDS. 1997;8:563-9.
41. Edge MD, Rimland D. Community-acquired bacteremia in HIV-positive patients: protective benefit of co-trimoxazole. AIDS. 1996;10:1635-9.
42. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med. 1995;333:845-51.
43. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med. 1997;336:1531-2.
44. Palella FJ, Delaneu KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al, and the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-60.
45. Michelet C, Arvieux C, François C, Besnier JM, Rogez JP, Breux JP, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS. 1998;12:1815-22.
46. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933-42.
47. Sullivan JH, Moore RD, Keruly JC, Chaisson RE. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30:S5-S14.
48. Mönkemüller KE, Call SA, Lazenby AJ, Wilcox CM. Declining prevalence of opportunisc gastrointestinal disease in the era of combination antiretroviral therapy. Am J Gastroenterol. 2000;95:457-62.
49. Benito N, Rañó A, Moreno A, González J, Luna M, Agustí C, et al. Pulmonary infiltrates in HIV-infected patients in the highly active antiretroviral therapy in Spain. J Acquir Immune Defic Syndr. 2001;27:35-43.
50. Benito N, Moreno A, Filella X, Miró JM, González J, Pumarola T, et al. Inflammatory responses in blood samples of human immunodeficiency virus -infected patients with pulmonary infections. Clin Diagn Lab Immun. 2004;11:608-14.
51. Murray J, Felton CP, Garay SM, Gottlieb MS, Hopewell PC, Stover DE, et al. Pulmonar complications of the acquired immunodeficiency syndrome: report of National Heart, Lung and Blood Institute Workshop. N Engl J Med. 1984;310:1682-8.
52. Lunngren JD, Pedersen C, Clumeck N, Gatell JM, Johnson AM, Ledererber B, et al. Survival differences in European AIDS patients 1979-1989. AIDS in Europe Study Group. Br Med J. 1994;308:1068-73.
53. Lungdren JD, Philips AN, Vella S, Katlama C, Ledergerber B, Johnson AM, et al. Regional differences in use of antiretrovirals and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J AIDS. 1997;16:93-9.
54. Hoover DR, Saah AJ, Bacellar H, Phair J, Detels R, Anderson R, et al, for the Multicenter AIDS Cohort Study. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med. 1993;329:1922-6.
55. Muñoz A, Schager LK, Bacellar H, Speizer I, Vermund SH, Detels R, et al. Trends in the incidence and outcomes defining acquired immunodeficiency syndrome (AIDS) in the multicenter AIDS cohort study: 1985-1999. Am J Epidemiol. 1993;137:423-8.
56. Montaner JS, Le T, Hogg R, Ricketts M, Sutherland D, Strathdee SA, et al. The changing spectrum of AIDS index diseases in Canada. AIDS. 1994;8:693-6.
57. Dore GJ, Hoy JF, Mallal SA, Li Y, Mijch AM, French MA, et al. Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort. J Acquir Immune Defic Syndr Hum Retravirol. 1997;16:39-43.
58. Masur H. Human Immunodeficiency virus-related opportunistic infections in the era of highly active antiretroviral therapy. En: Scheld WM, Craig WA, Hughes JM, editors. Emerging infections 4. Washington: ASM Press; 2000. p. 165-86.
59. Wolgg AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest. 2001;120:1888-93.
60. European Centre for the Epidemiological Monitoring of AIDS. HIV/AIDS surveillance in Europe. 1994-1996. St. Maurice, France; 1996.
61. Dore GJ, Li Y, McDonald A, Ree H, Kaldo JM. Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. J Acquir Immune Defic Syndr. 2002;29:388-95.
62. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;50:2487-98.
63. Blaxhult A, Kirk O, Pedersen C, Dietrich M, Barton SE, Gatell JM, et al. Regional differences in presentation of AIDS in Europe. Epidemiol Infect. 2000;125:143-51.
64. Pulvirenti J, Herrera P, Venkataraman P, Ahmed N. Pneumocystis carinii pneumonia in HIV-infected patients in the HAART era. AIDS Patient Care STDS. 2003;17:261-5.
65. Smith E, Orholm MK. Danish AIDS patients 1988-1993: a recent decline in Pneumocystis carinii pneumonia as AIDS-defining disease related to the period of known HIV positivity. Scand J Infect Dis. 1994;26:517-22.
66. Stoehr A, Arasteh K, Staszewski S, Brockmeyer N, Albrecht H, Mertenskotter T, et al. Pneumocystis carinii pneumonia in the Federal Republic of Germany in the era of changing antiretroviral therapy - IDKF 13 - German AIDS Study Group (GASG/IdKF). Eur J Med Res. 1999; 27;131-4.
67. Edge MD, Rimland D. Reasons for failure of prophylaxis for Pneumocystis carinii pneumonia: a retrospective study and review. AIDS. 1999;13:991-2.
68. Pradier C, Pesce A, Taillan B, Roger PM, Bentz L, Dellamonica P. Reducing the incidence of Pneumocystis carinii pneumonia: a persisting challenge. AIDS. 1997;11:832-3.
69. Phair J, Muñoz A, Detels R, Kaslow R, Rinaldo C, Saah A, and the Multicenter AIDS Cohort Study Group. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med. 1990;322:161-5.
70. Grupo PcoHS. Design of a prospective study of the pulmonary complications of human immunodeficiency virus infection. J Clin Epidemiol. 1990;46:497-507.
71. Wallace JM, Rao AV, Glassroth J, Hausen NI, Rosen MJ, Arakaki C, et al, and the Pulmonary Complications of HIV Infections Study Group. Respiratory illness in persons with human immunodeficiency virus infection. Am Rev Respir Dis. 1993;148:1523-9.
72. Paul S, Gilbert HM, Ziecheck W, Jacobs J, Septowitz KA. The impact of potent antirretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS. 1999;13:415-8.
73. Altés J, Guadarrama M, Force L, Tapiz A, Vilaró J, García I, and the Catalonian County Hospitals HIV Infection Study Group. The impact of highly active antirretroviral therapy on HIV-related hospitalizations in 17 county hospitals in Catalonia, Spain. AIDS. 1999;13:1418-9.
74. Magnenat JL, Nicod LP, Auckenthaler R, Junod AF. Mode of presentation and diagnosis of bacterial pneumonia in human immunodeficiency virus-infected patients. Am Rev Respir Dis. 1991;144:917-22.
75. Ferrer M, Torres A, Xaubet A, Puig de la Bellacasa J, Agusti C, Gonzalez J, et al. Diagnostic value of telescoping plugged catheters in HIV-infected patients with pulmonary infiltrates. Chest. 1992;102:76-83.
76. Polsky B, Gold JWM, Whimbey E, Dryjanski J, Brown AE, Schiffman G, et al. Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1986;104:38-41.
77. Baril L, Astagneau P, Nguyen J, Similowski T, Mengual X, Beigelman C, et al. Pyogenic bacterial pneumonia in human immunodeficiency virus-infected inpatients: a clinical, radiological, microbiological and epidemiological study. Clin Infect Dis. 1998;26:964-71.
78. Tumbarello M, Tacconelli E, de Gaetano Donati K, Cauda R. HIV-associated bacterial pneumonia in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:208-9.
79. Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest. 2001;120: 1888-93.
80. De Gaetano Donati K, Bertagnolio S, Tumbarello M, Taconelli E, Cataldo M, Longo R, et al. Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects. Int J Antimicrob Agents. 2000;16:357-60.
81. Sullivan JH, Moore RD, Keruly JC, Chaisson RE. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med. 2000;162:64-7.
82. Hanson DL, Chu SY, Farizo KM, Ward JW, and the Adult and Adolescent Spectrum of HIV Disease Study Group. Distribution of CD4+ lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. Arch Intern Med. 1995;155:1537-42.
83. Boschini A, Smacchia C, Di Fine M, Schiesari A, Ballarini P, Arlotti M, et al. Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects. Clin Infect Dis. 1996;23:107-13.
84. Witt DJ, Craven DE, McCabe WR. Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex. Am J Med. 1987;82:900-6.
85. Rimland D, Navin TR, Lennox JL, Jernigan JA, Kaplan J, Erdman D, et al. Prospective study of etiologic agents of community acquired pneumonia in patients with HIV infection. AIDS. 2002;16:85-95.
86. Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection. Epidemiologic, clinical and immunologic perspectives. Ann Intern Med. 1992;117:314-24.
87. Feldman C, Glatthaar M, Morar R, Mahomed AG, Kaka S, Cassel M, et al. Bacteriemic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults. Chest. 1999;116:107-14.
88. Nuorti JP, Butler JC, Gelling L, Kool JI, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med. 2000;132:182-90.
89. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE, and the Adult and Adolescent Spectrum of HIV Disease Project. Pneumoccal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis. 2001;32:794-800.
90. French N, Gilks CF, Mujugira A, Fasching C, O'Brien J, Janoff EN. Pneumococcal vaccination in HIV-infected adults in Uganda: humonal response and two vaccine failures. AIDS. 1998;12:1683-9.
91. French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000;355:2106-11.
92. Breiman RF, Keller DW, Phelan MA, Sniadack DH, Sthephens DS, Rimland D, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med. 2000;160:2633-8.
93. Spoulou V, Gilks CF, Ioannidis JPA. Protein conjugate pneumococcal vaccines. Offer new opportunities for high risk individuals but skill lack robust evidence. BMJ. 2002;324:750-1.
94. Tasker SA, Wallace MR, Rubins JB, Paxton WB, O'Brien J, Janoff EN. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis. 2002;34:813-21.
95. López-Palomo C, Martín-Zamorano M, Benítez E, Fernández-Gutiérrez C, Guerrero F, Rodríguez-Iglesias M, et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol. 2004;72:517-24.
96. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine. 2004;22: 2006-12.
97. CDC. USPHS/IDSA guidelines for the prevention of opportunistic infections in people infected with human immunodeficiency virus. MMWR. 1999;48:1-66.
98. Cordero E, Pachón J, Rivero A, Girón JA, Gómez-Mateos J, Merino MD, et al. Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. Clin Infect Dis. 2000;30:461-5.
99. Levine SJ, White DA, Fels AD. The incidence and significance of Staphylococcus aureus in respiratory cultures from patients infected with the human immunodeficiency virus. Am Rev Respir Dis. 1990; 141:89-93.
100. Afessa B, Green B. Bacterial pneumonia in hospitalized patients with HIV infection. The pulmonary complications, ICU support, and prognostic factors of hospitalized patients with HIV (PIP) study. Chest. 2000;117:1017-22.
101. Tumbarello M, Tacconelli E, de Gaetano Doneti K, Bertagnolio S, Cataldo M, Pirronti T, et al. Nosocomial bacterial pneumonia in human immunodeficiency virus infected subjects: incidence, risk factors and outcome. Eur Respir J. 2001;17:636-40.
102. Santín Cerezales M, Aranda Sánchez M, Podzamcer Palter D, Maiques Llacer JM, Rugí Rigau G, Gudiol Munté F. Espectro de la infección broncopulmonar por Pseumomonas aeruginosa en pacientes infectados por el virus de la inmunodeficiencia humana. Rev Clin Esp. 1996;196:692-7.
103. Pedro-Botet ML, Sabrià M, Sopena N, García- Núñez M, Domínguez MJ, Reynaga E, et al. Legionnaires diseases and HIV infection. Chest. 2003;124:543-7.
104. Marston BJ, Lipman HB, Breiman RF. Surveillance for Legionnaires' disease. Risk factors for morbidity and mortality. Arch Intern Med. 1994;154:2417-22.
105. Blatt SP, Dolan MJ, Hendrix CW, Melcher GP. Legionnaires' disease in human immunodeficiency virus-infected patients: eight cases and review. Clin Infet Dis. 1994;18:227-32.
106. Gutiérrez Rodero F, Ortiz de la Tabla V, Martínez C, Masia MM, Chiner E, Calpe JL. Legionnaires' disease in patients infected with human immunodeficiency virus. Clin Infect Dis. 1995;21:712-3.
107. Sene D, Bossi P, Thomas L, Ghosn J, Zeller V, Caumes E, et al. Legionellosis in HIV-1 infected patients: 4 cases repots. Press Med. 2002;31:356-8.
108. Pedro-Botet ML, García Cruz A, Sopena N, Domínguez MJ, Sarroca O, Rey Joly C, et al. Legionelosis e infección por el virus de la inmunodeficiencia humana: ¿infección oportunista? Med Clin (Barc). 2004;123: 582-4.
109. Centers for Disease control and Prevention. Tuberculosis morbidity - United States. MMWR. 1996;45:365-70.
110. Markowitz N, Hansen N, Hopewell PC, Glassroth J, Kvale PA, Mangura BT. Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med. 1997;126:123-32.
111. Kirk O, Gatell JM, Mocroft A, Pedersen C, Proenca R, Brettle RP, et al. Infections with Mycobacterium tuberculosis y Mycobacterium avium among HIV-patientes after the introduction of highly active antiretroviral therapy. Am J Respir Crit Care Med. 2000;162:865-72.
112. Sudre P, Hirschel BJ, Gatell JM, Schwander S, Vella S, Katlama C, et al. Tuberculosis among European patients with the acquired immune deficiency syndrome: The AIDS in Europe Study Group. Tuber Lung Dis. 1996;77:322-8.
113. Guelar A, Gatell JM, Verdejo J, Podzamczer D, Lozano L, Aznar E, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS. 1993;7:1345-9.
114. Juffermans NP, Verbon A, Danner SA, Kuijper EJ, Speelman P. Mycobacterium xenopi in HIV-infected patients: an emerging pathogen. AIDS. 1998;12:1661-6.
115. Orlovic D, Kularatne R, Ferraz V, Smego RA. Dual pulmonary infection with Mycobacterium tuberculosis and Pneumocystis carinii in patients with human immunodeficiency virus. Clin Infect Dis. 2001;32: 289-94.
116. Schleicher GK, Feldman C. Dual infection with Streptococcus pneumoniae and Mycobacterium tuberculosis in HIV-seropositive patients with community acquired pneumonia. Int J Tuberc Lung Dis. 2003;7:1207-8.
117. Braun M, Killam D, Remick S, Ruckdeschel J. Lung cancer in patients seropositive for human immunodeficiency virus. Radiology. 1990;175: 341-3.
118. Fraire A, Awe R. Lung cancer in association with human immunodeficiency virus infection. Cancer. 1992;70:432-6.
119. Msur H, Shelhamer J. Empiric outpatient management of HIV-related pneumonia: economical or unwise? Ann Intern Med. 1996;124:451-3.
120. Salzman SH. Bronchoscopic and other invasive sampling techniques in the diagnosis of pulmonary complications of HIV infection. En: Rosen MJ, Beck JM, editores. Human immunodeficiency virus and the lung. New York: Marcel Dekker; 1998. p. 195-227.
121. Cordero E, Pachon J, Rivero A, Girón-Gonzalez JA, Gómez-Mateos J, Merino MD, et al. Usefulness of sputum culture for diagnosis of bacterial pneumonia in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2002;21:362-7.
122. Gutiérrez F, Masiá M, Carlos Rodríguez J, Ayelo A, Soldán B, Cebrián L, et al. Evaluation of the immunochromatographic binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community -acquired pneumonia in Spain. Clin Infect Dis. 2003;36:286-92.
123. Villuendas MC, Remacha MA, Echávarri B, Lezcano MA, Omeñaca M, Arazo P, et al. Neumonías diagnosticadas por broncoscopia en pacientes VIH-positivos. Enferm Infecc Microbiol Clin. 1996;14:314-6.
124. Narayanswami G, Salzman SH. Bronchoscopy in the human immunodeficiency virus-infected patient. Semin Respir Infect. 2003;18:80-6.
125. Mundy LM, Autwaerter PG, Oldach D, Warner ML, Burton A, Vanc Gaydos CA, et al. Community acquired pneumonia: impact of immune status. Am J Respir Crit Care Med. 1995;152:1309-15.
126. Torres A, El-Ebiary M, Marrades R, Miró JM, Gatell JM, Sánchez-Niento JM, et al. Aetiology and prognosis factors of patients with AIDS presenting life-threatening acute respiratory failure. Eur Respir J. 1995;8: 1922-8.
127. Fernández P, Torres A, Miró JM, Vieigas C, Mallolas J, Zamora L, et al. Prognostic factors influencing the outcome in Pneumocystis carinii pneumonia in pacients with AIDS. Thorax. 1995;50:668-71.
128. Azoulay E, Parrot A, Flahault A, Cesari D, Lecomte I, Roux P, et al. AIDS-related Pneumocystis carinii pneumonia in the era of adjunctive steroids. Implication of BAL neutrophilia. Am J Respir Crit Care Med. 1999;160:493-9.
129. Fernández Cruz A, Pulido Ortega F, Peña Sánchez de Rivera JM, Sanz García M, Lorenzo Hernández F, González García J, et al. Factores pronósticos de mortalidad durante el episodio de neumonía por Pneumocystis carinii en pacientes con infección por VIH. Rev Clin Esp. 2002;202:418-22.
130. Calderon EJ, Varela JM, Medrano FJ, Nieto V, González-Becerra C, Respaldiza N, et al. Epidemiology of Pneumocystis carinii pneumonia in southern Spain. Clin Microbiol Infect. 2004;10:673-6.
131. Wachter RM, Luce JM, Safrin S, Berrios DC, Charlebois E, Scitowsky AA. Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia and severe respiratori failure. JAMA. 1995; 273:230-5.
132. Morris A, Wachter RM, Luce J, Turner J, Huang L. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS. 2003;17:73-80.
133. Tumbarello M, Tacconelli E, de Gaetano K, Ardito F, Pirronti T, Cauda R, et al. Bacterial pneumonia in HIV-infected patients. Analysis of risk factors and prognosis indicators. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;16:39-45.
134. Janoff EN, Rubins JB. Invasive pneumococcal disease in the immunocompromised host. Microbial Drug Resist. 1997;3:215-32.
135. Hibbs JR, Douglas JM Jr, Judson FN, McGill WL, Rietmeijer CAM, Janoff EN. Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994. Clin Infect Dis. 1997;25:195-9.
136. Pesola GR, Charles A. Pneumococcal bacteremia with pneumonia: mortality in acquired immunodeficiency syndrome. Chest. 1992;101:150-5.